4 completed, 2 active not recruiting, 1 recruiting. 7 Phase 2, 6 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 7 | Completed 4, Active not recruiting 2, Recruiting 1 |
| Phase 1 | 6 | Completed 4, Active not recruiting 2 |
Follow INO-9012: new trials by email Literature Review of INO-9012 trials Research Report on INO-9012
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Personalized Neoantigen Vaccine Plus IL-12 (INO-9012) Versus Active Surveillance in Subjects With High-Risk HCC GNOS-PV02 + INO-9012 delivered by intradermal injection, followed by electroporation, Electroporation Device, INO-9012 - HCC | Phase 2 | Recruiting | Geneos Therapeutics | 90 | 2026-09-01 | 2026-09-23 |
| GNOS-PV02 Personalized Neoantigen Vaccine, INO-9012 and Pembrolizumab in Subjects With Advanced HCC GNOS-PV02, INO-9012, Pembrolizumab - HCC | Phase 1 / Phase 2 | Active not recruiting | Geneos Therapeutics | 36 | 2020-03-01 | 2026-09-24 |
| Therapeutic Vaccination in Treated HIV Disease PENNVAX-GP, INO-6145, INO-9012 - HIV-1-infection | Phase 1 / Phase 2 | Completed | Steven Deeks | 56 | 2018-08-01 | 2023-05-31 |
| INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma INO-5401, INO-9012, Atezolizumab - Urothelial Carcinoma | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 35 | 2018-07-24 | 2026-09-02 |
| INO-5401 and INO-9012 Delivered by Electroporation (EP) in Combination With Cemiplimab (REGN2810) in Newly-Diagnosed Glioblastoma (GBM) INO-5401, INO-9012, Cemiplimab - Glioblastoma | Phase 1 / Phase 2 | Active not recruiting | Inovio Pharmaceuticals | 52 | 2018-05-31 | 2026-10-22 |
| Study of HPV Specific Immunotherapy in Participants With HPV Associated Head and Neck Squamous Cell Carcinoma INO-3112, CELLECTRA™-5P - Head and Neck Squamous Cell Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 22 | 2014-08-13 | 2021-01-22 |
| A Study of INO-3112 DNA Vaccine With Electroporation in Participants With Cervical Cancer INO-3112, CELLECTRA™-5P - Cervical Cancer | Phase 1 / Phase 2 | Completed | Inovio Pharmaceuticals | 10 | 2014-06-06 | 2021-02-21 |
Carcinoma, Transitional Cell (1) · Glioblastoma (1) · Uterine Cervical Neoplasms (1)
Inovio Pharmaceuticals (4) · Geneos Therapeutics (2) · Steven Deeks (1)
United States (7) · New Zealand (2)
Jeffrey Skolnik, MD (4) · Steven Deeks, MD (1)
U01AI131296 (1)